I'm LongbridgeAI, I can summarize articles.AC Immune SA has called an Extraordinary General Meeting for October 2, 2026, to elect veteran biopharma financier Tom Graney to its Board of Directors and the Audit and Finance Committee. This move follows founder Andrea Pfeifer's retirement and aims to strengthen financial oversight during a leadership transition. Graney brings extensive experience in raising over $500 million. Existing board member Carl June will step down. The company is advancing key pipeline assets, including a Fast Track-designated Parkinson’s program.
The latest update is out from AC Immune SA ( (ACIU) ).
On September 2, 2026, AC Immune SA called an Extraordinary General Meeting set for October 2, 2026, as part of a broader leadership and governance reshaping following the founder’s retirement at the June AGM. The meeting invitation outlines detailed voting and attendance procedures for registered and beneficial shareholders, including electronic instructions through Computershare and representation via an independent proxy in Switzerland.
The Board will ask shareholders to elect veteran biopharma executive Tom Graney to the Board of Directors, with an intended role on the Audit and Finance Committee through the 2027 AGM, while existing member Carl June will step down effective at the EGM. Graney’s prior tenure on AC Immune’s board and extensive U.S. public markets and financing experience, including helping raise more than $500 million, are expected to strengthen the company’s financial oversight as it advances its Fast Track-designated Parkinson’s program and other key pipeline assets.
The EGM arrangements underscore AC Immune’s effort to manage a sensitive transition period while maintaining investor engagement, with strict eligibility dates for voting and clear documentation requirements for in-person or proxy participation. For stakeholders, the proposed board change and emphasis on seasoned financial leadership signal a drive to capitalize on recent clinical progress and reinforce governance as the company navigates capital-intensive late-stage development.
The most recent analyst rating on (ACIU) stock is a Buy
with a $12.00 price target.
To see the full list of analyst forecasts on AC Immune SA stock,
see the ACIU Stock Forecast page.
Spark’s Take on ACIU Stock
According to Spark, TipRanks’ AI Analyst, ACIU is a Neutral.
The score is primarily constrained by weak financial performance—persistent losses and a 2025 return to heavy cash burn—despite the benefit of low leverage on the balance sheet. Technicals add further pressure as the stock trades below key longer-term moving averages. Valuation contributes only a modest offset because the negative P/E reduces the usefulness of earnings-based valuation and there is no dividend yield provided.
To see Spark’s full report on ACIU stock,
click here.
More about AC Immune SA
AC Immune SA is a Swiss clinical-stage biopharmaceutical company focused on neurodegenerative and inflammatory diseases, with a pipeline that includes active immunotherapies and small-molecule inhibitors. Its key programs target early Parkinson’s disease, cardiovascular inflammation and Alzheimer’s disease, reflecting a strategic focus on high-need CNS and systemic indications.
The company is advancing ACI-7104, an anti-alpha-synuclein active immunotherapy that recently received FDA Fast Track designation, alongside ACI-19764, an NLRP3 inhibitor now in Phase 1b in patients with cardiovascular risk factors. It is also developing ACI-24, an anti-Abeta active immunotherapy in a Phase 1b/2 Alzheimer’s trial in collaboration with Takeda, signaling an emphasis on partnering and late-stage development.
Following the June 2026 AGM and the retirement of co-founder Andrea Pfeifer after 23 years, AC Immune is undergoing a management transition led by interim CEO and chair Martin Zügel. The firm’s governance and shareholder processes are structured around Swiss corporate law and cross-border investor participation, with voting arrangements coordinated via Computershare and an independent proxy in Lausanne.
Average Trading Volume: 248,553
Technical Sentiment Signal: Hold
Current Market Cap: $272.8M
For a thorough assessment of ACIU stock, go to TipRanks’ Stock Analysis page.